+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Generic Drugs Market by Product Type, Drug Class, Route of Administration, Patient Type, Therapeutic Application, Distribution Channel - Global Forecast to 2030- Product Image
Generic Drugs Market by Product Type, Drug Class, Route of Administration, Patient Type, Therapeutic Application, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Generic Drugs Market by Product Type, Drug Class, Route of Administration, Patient Type, Therapeutic Application, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888623
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The generic drugs market continues to gain strategic importance as healthcare systems prioritize access, cost-effectiveness, and reliability. Senior decision-makers require clear visibility into evolving dynamics and actionable insights to inform resource allocation and business development in this highly competitive segment.

Market Snapshot: Generic Drugs Market Overview

The Generic Drugs Market grew from USD 415.28 billion in 2024 to USD 451.61 billion in 2025. It is expected to continue growing at a CAGR of 9.08%, reaching USD 699.65 billion by 2030. This steady expansion reflects increased demand for affordable therapies as both healthcare budgets and chronic disease incidence expand globally. Market participants benefit from scale and accelerated portfolio growth amid a landscape defined by regulatory innovation, technology adoption, and patient-centric healthcare.

Scope & Segmentation

This comprehensive report structures the generic drugs market across multiple key segments, enabling granular evaluation of growth opportunities and competitive positioning.

  • Product Types: Over-the-counter (OTC) generic drugs, Prescription generic drugs.
  • Drug Classes: Analgesics, Antibiotics, Antidepressants, Antidiabetics, Antihistamines, Antihypertensives.
  • Routes of Administration: Inhalations, Injectables, Oral, Topical.
  • Patient Types: Adult, Geriatric, Pediatric.
  • Therapeutic Applications: Anti-infectives, Cardiovascular, Central Nervous System (CNS), Diabetes, Oncology, Respiratory.
  • Distribution Channels: Hospital pharmacies, Retail pharmacies, Online pharmacies.
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Amneal Pharmaceuticals, Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Bausch Health Companies Inc., Baxter International Inc., Biocon Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Endo, Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Krka d.d., Lupin Limited, Pfizer Inc., Sandoz Group AG, Sanofi SA, STADA Arzneimittel AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., Zydus Lifesciences Limited.

Key Takeaways for Decision-Makers

  • Regulatory advancement has shortened approval pathways, supporting robust pipeline expansion and accelerating time-to-market for new generics.
  • Investments in digital technologies and automation are enabling manufacturers to improve batch consistency and reduce operational costs.
  • Patient-centric models are leading to greater innovation, especially in complex generics and differentiated formulations addressing unmet clinical needs.
  • Strategic alliances and licensing agreements between generics and biotech firms are facilitating the development of biosimilars and specialty drugs.
  • Supply chain diversification and digital traceability systems are now central to managing risk and enhancing resilience amid regional and global disruptions.
  • The rise of e-pharmacies and omnichannel distribution is expanding market reach and supporting new models of patient engagement.

Tariff Impact: Navigating the 2025 US Regulatory Environment

The upcoming US tariff regime in 2025 brings added complexity to cost structures and procurement strategies in the generic drugs market. Companies importing active pharmaceutical ingredients and finished products must reevaluate sourcing, often shifting toward domestic production or tariff-exempt suppliers. Lean operational models, renegotiated contracts, and regional warehousing strategies will become essential for maintaining margins. The new tariff environment also stimulates public-private initiatives focused on boosting domestic capacity, prompting a broader industry transition toward supply chain localization and strategic resilience.

Methodology & Data Sources

This report uses a mixed-methods framework featuring executive interviews, industry roundtables, and secondary research from peer-reviewed literature, regulatory filings, and annual reports. Quantitative insights are triangulated across proprietary databases, ensuring consistency and reducing bias. Ongoing validation with healthcare economists and regulatory consultants strengthens the reliability of findings.

Why This Report Matters for Senior Leaders

  • Enables data-driven planning by revealing the latest market forces shaping generics, including policy shifts and digital transformation.
  • Supports risk mitigation and strategic agility by outlining actionable opportunities across technology adoption, supply chain design, and commercial models.
  • Empowers executive teams to optimize product portfolios and expand market reach through detailed segmentation and competitive benchmarking.

Conclusion

As the generic drugs market evolves, strategic adaptability and investment in innovation are essential for capturing growth. Senior decision-makers can leverage this report’s insights to navigate regulatory, technological, and competitive shifts, ensuring long-term success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Generic Drugs Market, by Product Type
8.1. Introduction
8.2. Over-the-Counter (OTC) Generic Drugs
8.3. Prescription Generic Drugs
9. Generic Drugs Market, by Drug Class
9.1. Introduction
9.2. Analgesics
9.3. Antibiotics
9.4. Antidepressants
9.5. Antidiabetics
9.6. Antihistamines
9.7. Antihypertensives
10. Generic Drugs Market, by Route of Administration
10.1. Introduction
10.2. Inhalations
10.3. Injectables
10.4. Oral
10.5. Topical
11. Generic Drugs Market, by Patient Type
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Generic Drugs Market, by Therapeutic Application
12.1. Introduction
12.2. Anti-infectives
12.3. Cardiovascular
12.4. Central Nervous System (CNS)
12.5. Diabetes
12.6. Oncology
12.7. Respiratory
13. Generic Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.2.1. Hospital Pharmacies
13.2.2. Retail Pharmacies
13.3. Online Pharmacies
14. Americas Generic Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Generic Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Generic Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. Alembic Pharmaceuticals Limited
17.3.3. Alkem Laboratories Limited
17.3.4. Amneal Pharmaceuticals, Inc.
17.3.5. Aspen Pharmacare Holdings Limited
17.3.6. Aurobindo Pharma Limited
17.3.7. Bausch Health Companies Inc.
17.3.8. Baxter International Inc.
17.3.9. Biocon Limited
17.3.10. Cipla Limited
17.3.11. Dr. Reddy’s Laboratories Ltd.
17.3.12. Eli Lilly and Company
17.3.13. Endo, Inc.
17.3.14. Fresenius SE & Co. KGaA
17.3.15. GlaxoSmithKline PLC
17.3.16. Glenmark Pharmaceuticals Limited
17.3.17. Hikma Pharmaceuticals PLC.
17.3.18. Intas Pharmaceuticals Ltd.
17.3.19. Krka, d. d.
17.3.20. Lupin Limited
17.3.21. Pfizer, Inc.
17.3.22. Sandoz Group AG
17.3.23. Sanofi SA
17.3.24. STADA Arzneimittel AG
17.3.25. Sun Pharmaceutical Industries Limited
17.3.26. Teva Pharmaceutical Industries Ltd.
17.3.27. Viatris Inc.
17.3.28. Zydus Lifesciences Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. GENERIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. GENERIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. GENERIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. CANADA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. MEXICO GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. GERMANY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. GERMANY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 104. FRANCE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. FRANCE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. FRANCE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. FRANCE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. FRANCE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 118. ITALY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. ITALY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. ITALY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. ITALY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. ITALY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 125. SPAIN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. SPAIN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. SPAIN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 153. DENMARK GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. DENMARK GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. DENMARK GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. DENMARK GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. DENMARK GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 167. QATAR GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. QATAR GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. QATAR GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. QATAR GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. QATAR GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. FINLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. FINLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. FINLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. FINLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. SWEDEN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. NIGERIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 195. EGYPT GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. EGYPT GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. EGYPT GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. EGYPT GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. EGYPT GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 202. TURKEY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. TURKEY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. TURKEY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. TURKEY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. TURKEY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. NORWAY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. NORWAY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. NORWAY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. NORWAY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 223. POLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. POLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. POLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. POLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. POLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 245. CHINA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. CHINA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. CHINA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. CHINA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. CHINA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 252. INDIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. INDIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 254. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. INDIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. INDIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. INDIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 259. JAPAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. JAPAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 261. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. JAPAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. JAPAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. JAPAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 287. THAILAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. THAILAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. THAILAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. THAILAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. THAILAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 319. VIETNAM GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 320. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. VIETNAM GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 323. TAIWAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 326. TAIWAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 327. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. TAIWAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 329. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 330. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Generic Drugs market report include:
  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Limited
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Endo, Inc.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC.
  • Intas Pharmaceuticals Ltd.
  • Krka, d. d.
  • Lupin Limited
  • Pfizer, Inc.
  • Sandoz Group AG
  • Sanofi SA
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 451.61 Billion
Forecasted Market Value ( USD ) by 2030 $ 699.65 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

United States Generic Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

United States Generic Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • United States
From
North America Generic Drugs Market Report and Forecast 2024-2032 - Product Image

North America Generic Drugs Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • North America
From
Generic Drugs - Global Strategic Business Report - Product Image

Generic Drugs - Global Strategic Business Report

  • Report
  • 711 Pages
  • Global
From
Generic Injectables Market by Dimension Query Chat Segmentation - Global Forecast to 2030 - Product Image

Generic Injectables Market by Dimension Query Chat Segmentation - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Generic Oncology Drugs Market by Drug Type, Indication, Distribution Channel, Route of Administration, Therapy Line, Mechanism of Action, Formulation - Global Forecast to 2030 - Product Image

Generic Oncology Drugs Market by Drug Type, Indication, Distribution Channel, Route of Administration, Therapy Line, Mechanism of Action, Formulation - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From

About the Generic Drugs Market

The Generic Drugs market is a segment of the pharmaceutical industry that focuses on the production and sale of generic drugs. Generic drugs are copies of brand-name drugs that have the same active ingredients, dosage form, strength, route of administration, safety, efficacy, and intended use as the original drug. Generic drugs are typically much cheaper than their brand-name counterparts, making them a popular choice for consumers. Generic drugs are produced by a variety of companies, including large pharmaceutical companies, small generic drug manufacturers, and even generic drug divisions of brand-name drug companies. Generic drug companies must meet the same standards of quality, safety, and efficacy as brand-name drug companies. Some of the major companies in the Generic Drugs market include Teva Pharmaceuticals, Mylan, Sandoz, Sun Pharmaceuticals, Dr. Reddy's Laboratories, and Lupin. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.